REXULTI: payments to doctors
Payments that named REXULTI as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $54.5M
- Providers
- 105,433
- Transactions
- 882,775
- Average per transaction
- $62
The per-transaction average — $62 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 105,433 providers the average total is $517, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | $42,406,990 | 77.8% |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | $5,467,542 | 10.0% |
| Lundbeck LLC | $5,061,802 | 9.3% |
| H. Lundbeck A S | $1,182,256 | 2.2% |
| Otsuka Pharmaceutical Co., Ltd. | $384,524 | 0.7% |